You’re invited to a private, information-only webinar examining a philanthropic approach used by a small number of sophisticated donors to extend the long-term impact of charitable capital.

Charitable capital can be used to support a private company while still qualifying for a charitable tax deduction.

This session explains how established charitable vehicles, including donor-advised funds can back mission-driven companies addressing the root causes of major global challenges. 

Featured speakers

Randy Hyer, MD, PhD

Founder, Merlin Biotech
Dr. Hyer is a physician and biotechnology executive with more than 15 years of experience in vaccines, biologics, and infectious disease. He previously served as Senior Vice President of Global Medical Affairs at Moderna, where he played a central role in the FDA approval and global launch of the mRNA COVID-19 vaccine. Prior to Moderna, he led Clinical Development and Medical Affairs at Dynavax, contributing to the approval of HEPLISAV-B. He founded Merlin Biotech to advance next-generation solutions in pediatric cancer and infectious disease.

Lark Meadow

Co-Founder and CEO, Aeon Blue
Lark Meadow is a climate innovator focused on large-scale systems change and industrial decarbonization. She co-founded Aeon Blue with inventor and electrochemist Deóis Ua Cearnaigh. Aeon Blue is developing an integrated hydrogen and carbon capture platform that uses wind energy, seawater, and atmospheric carbon dioxide to produce cost-efficient eFuel, with potential applications in aviation and other hard-to-decarbonize sectors.

Additional Q and A support

Impact Assets, a charitable investment platform with over four billion dollars under management

Date: April 30

Time:  3:30pm EST
Format: Forty-five minute webinar followed by moderated discussion

This is an educational session only. There will be no fundraising solicitation.

For planning purposes, we would appreciate hearing from you by March 28th